Drug-drug interaction prediction: A Bayesian meta-analysis approach

Statistics in Medicine

Volumn 26, Issue 20, 2007, Pages 3700-3721

  Li, Lang ^a,c   Yu, Menggang ^a   Chin, Raymond ^b   Lucksiri, Aroonrut ^a   Flockhart, David A ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Area under the concentration curve ratio (AUCR); Bayesian model; Drug drug interaction (DDI); Meta analysis; Pharmacokinetics (PK); Prediction

Indexed keywords

KETOCONAZOLE; MIDAZOLAM;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL TRIAL; COMPUTER MODEL; COMPUTER SIMULATION; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG RESEARCH; HUMAN; MONTE CARLO METHOD; PREDICTION; PROBABILITY; SAMPLE SIZE; SENSITIVITY ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL;

ANTI-ANXIETY AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; DRUG INTERACTIONS; FORECASTING; HUMANS; KETOCONAZOLE; MIDAZOLAM; MODELS, STATISTICAL; PHARMACOKINETICS; UNITED STATES;

EID: 34548149708     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2837     Document Type: Article

References (43)

1. Rowland M, Tozer TN. Clinical Pharmacokinetics Concept and Applications (3rd edn). Lippincott Williams & Wilkins: London, 1995.
2. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measurement Data. Chapman & Hall: New York, 1995.
3. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacological Reviews 1998; 50(3):387-412.
4. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena Jr LR. Torsades de pointes occurring in association with terfenadine use. Journal of the American Medical Association 1990; 264(21):2788-2790.
5. Watabe T. Strategic proposals for predicting drug-drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs. Journal of Toxicological Sciences 1996; 21(5):299-300.
6. Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y, Watabe T. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metabolism and Disposition 1997; 25(5):270-273.
7. Yang J, Kjellsson M, Rostami-Hodjegan A, Tucker GT. The effects of dose staggering on metabolic drug-drug interactions. European Journal of Pharmaceutical Sciences 2003; 20(2):223-232.
8. DuMouchel W, Harris JE. Bayes methods for combining the results of cancer studies in human and other species. Journal of the American Statistical Association 1983; 78:293-315.
9. Pocock SJ, Hughes MD. Estimation issues in clinical trials and overviews. Statistics in Medicine 1990; 9:657-671.
10. Malec D, Sedransk J. Bayesian methodology for combining the results from different experiments when the specifications for pooling are uncertain. Biometrika 1992; 79:593-601.
11. Abrams K, Sanso B. Approximate Bayesian inference for random effects meta-analysis. Statistics in Medicine 1998; 17:201-218.
12. Wakefield JC, Rahman N. The combination of population pharmacokinetic studies. Biometrics 2000; 56(1): 263-270.
13. Lopes HF, Muller P, Rosner GL. Bayesian meta-analysis for longitudinal data models using multivariate mixture priors.Biometrics 2003; 59(1):66-75.
14. Wakefield JC. The Bayesian analysis of population pharmacokinetic models. Journal of the American Statistical Association 1996; 91:62-75.
15. Hastings WK. Monte Carlo sampling methods using Markov chains and their applications. Biometrika 1970; 57:97-109.
16. Li L, Brown MB, Lee KH, Gupta S. Estimation and inference for a spline-enhanced population pharmacokinetic model. Biometrics 2002; 58(3):601-611.
17. Li L, Lin X, Brown M, Gupta S, Lee KH. A population pharmacokinetic model with time-dependent covariates measured with errors. Biometrics 2004; 60:451-460.
18. Gascoigne EW, Barton GJ, Michaels M, Meuldermans W, Heykans J. The kinetics of ketoconazole in animals and man. Clinical Research Reviews 1981; 1(3):177-187.
19. Daneshmend TK, Warnock DW, Turner A, Roberts CJ. Pharmacokinetics of ketoconazole in normal subjects. Journal of Antimicrobial Chemotherapy 1981; 8(299-304).
20. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Parker G, Richardson MD, Roberts CJ. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. Journal of Antimicrobial Chemotherapy 1983; 12(2):185-188.
21. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ. Influence of food on the pharmacokinetics of ketoconazole. Antimicrobial Agents and Chemotherapy 1984; 25(1):1-3.
22. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrobial Agents and Chemotherapy 1986; 30(2):206-210.
23. FDA. Bioequivalence Reviews. 1999 [Available from http://www.fda.gov/cder/foi/anda/99/74-971_Ketoconazole.htm].
24. FDA. Bioequivalence Reviews, 1999 [Available from http://www.fda.gov/cder/anda/99/75-273_Ketoconazole.htm].
25. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics 1994; 55(5):481-485.
26. McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, Brucker MJ, Miller-Stein C, Osborne B, Waldman S. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. Journal of Clinical Pharmacology 1999; 39(12):1212-1220.
27. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clinical Pharmacology and Therapeutics 2002; 72(6):718-728.
28. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. Journal of Clinical Pharmacology 2003; 43(11):1274-1282.
29. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clinical Pharmacology and Therapeutics 1999; 66(5):461-471.
30. Gascoigne EW, BGJ, Michaels M, Meuldermans W, Heykants J. The kinetics of ketoconazole in animals and man. Clinical Research Reviews 1981; 1(3):177-187.
31. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Statistical Science 1992; 7:457-472.
32. Beal SL, Sheiner LB. Estimating population kinetics. Critical Reviews in Biomedical Engineering 1982; 8(3): 195-222.
33. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed model. Journal of the American Statistical Association 1993; 88:9-25.
34. Goldstein H. Nonlinear multilevel models with an application to discrete response data. Biometrika 1991; 78:45-51.
35. Rodriguez G, Goldman N. An assessment of estimation procedures for multilevel models with binary responses. Journal of the Royal Statistical Society, Series A 1995; 158:73-89.
36. Molenberghs G, Verbeke G. Models for Discrete Longitudinal Data. Springer-Verlag: New York, 2005.
37. Wolfinger R, O'Connell M. Generalized linear mixed models: a pseudo-likelihood approach. Journal of Statistical Computation and Simulation 1993; 48:233-243.
38. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy. Annals of Pharmacotherapy 1992; 26(4):502-509.
39. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. Journal of Pharmacology and Experimental Therapeutics 1990; 253(1):387-394.
40. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270(1): 414-423.
41. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, Tedder DR. Modeling inter-individual variation in physiological factors used in PBPK models of humans. Critical Reviews in Toxicology 2003; 33(5):469-503.
42. Martinez-Jorda R, Rodriguez-Sasianin JM, Calvo R. Serum binding of ketoconazole in health and disease. International Journal of Clinical Pharmacology Research 1990; 5:271-276.
43. i values and impact of CYP3A5 expression. Drug Metabolism and Disposition 1999; 27(2):180-187.